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Abstract
Recombinant production of therapeutically active proteins has become a central focus of contemporary life science
research. These proteins are often produced in mammalian cells, in order to obtain products with post-translational
modifications similar to their natural counterparts. However, in cases where a fast and flexible system for recombinant
production of proteins is needed, the use of mammalian cells is limited. The baculoviral insect cell system has proven to be a
powerful alternative for the expression of a wide range of recombinant proteins in short time frames. The major drawback
of baculoviral systems lies in the inability to perform mammalian-like glycosylation required for the production of
therapeutic glycoproteins. In this study we integrated sequences encoding Caenorhabditis elegans N-acetylglucosaminyl-
transferase II and bovine b1,4-galactosyltransferase I into the backbone of a baculovirus genome. The thereby generated
SweetBac virus was subsequently used for the production of the human HIV anti-gp41 antibody 3D6 by integrating heavy
and light chain open reading frames into the SweetBac genome. The parallel expression of target genes and
glycosyltransferases reduced the yield of secreted antibody. However, the overall expression rate, especially in the recently
established Tnao38 cell line, was comparable to that of transient expression in mammalian cells. In order to evaluate the
ability of SweetBac to generate mammalian-like N-glycan structures on 3D6 antibody, we performed SDS-PAGE and tested
for the presence of terminal galactose using Riccinus communis agglutinin I. The mammalianised variants of 3D6 showed
highly specific binding to the lectin, indicating proper functionality. To confirm these results, PNGase A released N-glycans
were analyzed by MALDI-TOF-MS and shown to contain structures with mainly one or two terminal galactose residues. Since
the presence of specific N-glycans has an impact on antibodies ability to exert different effector functions, we tested the
binding to human Fc gamma receptor I present on U937 cells.
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Introduction
The use of insect cells for the production of therapeutically
active proteins has gained increasing importance over the last
decade, highlighted by the market entry of the human papilloma
virus vaccine Cervarix
TM [1]. Nowadays, a set of different insect
cell lines, suitable for the baculovirus-driven production of
recombinant proteins, is available. The most popular ones are
Spodoptera frugiperda Sf9 cells [2], Spodoptera frugiperda Sf21 cells [3]
and Trichoplusia ni BTI-TN5B1-4 ‘‘High Five’’ (‘‘Hi5’’) cells [4].
More recently, a new Trichoplusia ni cell line, BTI-Tnao38, has been
established [5]. A major limitation regarding the production of
therapeutic proteins in insect cell lines is the lack of complex type
N-glycans, often leading to a severely reduced efficacy. N-glycans
found on insect cell expressed proteins are mainly of a high
mannose type or non-fucosylated and core-fucosylated tri-
mannose structures [6].
In the past, several approaches have served to improve N-linked
glycosylation in lepidopteran insect cell lines by expressing
additional glycosyltransferases. In a first trial, Sf9 cells were co-
infected with standard baculovirus vectors expressing human b1,2-
N-acetylglucosaminyltraferase I (GnTI) and a fowl plague virus
haemagglutinin (HA). Analysis of HA glycosylation patterns gave a
four fold increase in the amount of terminal N-acetylglucosamine
(GlcNAc) indicating the proper functionality of human GnTI in
insect cells [7]. In another approach, the use of a recombinant
baculovirus expressing a bovine b1,4-galactosyltransferase driven
by the immediate early promoter 1 (IE1) was investigated. It could
be shown that the baculovirus envelope protein gp64 was modified
by an additional galactose on at least one N-linked oligosaccharide
side chain [8]. These strategies are based on transient expression
of glycosyltransferases. Other studies have evaluated the use of
stable integration for modifying insects N-linked glycosylation
pathways. Hollister et al (1998) constructed a plasmid expressing a
bovine b1,4-galactosyltransferase controlled by the baculoviral IE1
promoter and stably integrated it into the genome of Sf9 cells. A
clone that has been selected for high enzymatic activity produced a
galactosylated ‘‘human tissue plasminogen activator’’ protein after
infection with the recombinant baculovirus [9]. The production of
terminally sialylated biantennary N-glycans was the next step in
glycoengineering insect cells. Several studies have shown that the
stable integration of b1,4-galactosyltransferase and a2,6-sialyll-
transferase leads to partially sialylated gp64 after infection with the
corresponding recombinant baculovirus [10,11]. To further
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glycosyltransferases was integrated into the genome of Sf9 cells
[12]. Due to the fact that the intracellular levels of sialic acid and
CMP-sialic acid, necessary for proper sialylation, are very low in
insect cells, a new transgenic Sf9 insect cell line was generated.
This was achieved by the additional integration of genes encoding
sialic acid synthetase and CMP-sialic acid synthetase leading to a
total number of 7 constitutively expressed glycozymes [13]#. The
drawback with using such a setup is a possible metabolic overload
for the transgenic cell line, leading to reduced growth character-
istics and long-term stability as well as reduced yields of
recombinantly produced proteins. Furthermore, the altered
glycosylation pattern might influence the functionality of cellular
proteins and have a wider impact on the robustness of the system.
To overcome these problems, a recent study has reported the
generation of a new transgenic Sf9 cell line with an inducible
mammalian-like protein N-glycosylation machinery [14]. What
still remains is the fact that all these approaches are based on Sf9
cells. However, for the expression of secreted proteins, cell lines
derived from Trichoplusia ni have been demonstrated to produce
significantly higher amounts in many cases [15,16]. Therefore, we
decided to revive the idea of using the baculovirus itself for
glycoengineering purposes. The MultiBac platform, which is an
advanced version of the Bac-to-Bac system, provides the possibility
of flexible multigene expression using a single baculovirus vector
[17–20]. In this study we evaluated the use of MultiBac for the
generation of an efficient platform for the production of properly
glycosylated proteins in lepitopteran insect cells other than the
commonly used Sf9 cells.
Materials and Methods
All DNA manipulations were carried out essentially as
summarised by Sambrook et al. [21]#. Restriction enzymes, T4
DNA ligase and Calf Intestinal Alkaline Phosphatase were
purchased from New England Biolabs (Ipswich, USA). DNA
polymerase was purchased from Novagen (Darmstadt, Germany).
All enzymes were used according to manufacturer’s recommen-
dation. All primers and oligos were synthesised by Sigma-Aldrich
(St. Louis, USA).
Cells and viruses
Spodoptera frugiperda Sf9 cells (ATCC CRL-1711) [2], Trichoplusia
ni BTI-TN5B1-4 ‘‘High Five’’ (‘‘Hi5’’) cells (ATCC CRL-10859)
[4] and Trichoplusia ni BTI-Tnao38 cells [5] were grown in IPL-41
medium (SAFC Biosciences, St. Louis, USA) containing yeast
extract, a lipid mixture supplemented with either 0% or 3% fetal
calf serum (FCS) at 27uC using T-flasks.
Human U937 leukemic monocyte lymphoma cells (ATCC
CRL-1593.2) were cultivated in RPMI1640 medium (PAA,
Pasching, Austria) containing 10% FCS and 4 mM glutamine at
37uC using T-flasks. Recombinant Autographa californica nucleopo-
lyhedroviruses were isolated and plaque purified by standard
procedures. Viral titres were determined by plaque assay using 10-
fold dilution series (n=3).
Construction of SweetBac
The Caenorhabditis elegans N-acetylglucosaminyltransferase II
(GnTII) was PCR-amplified from a plasmid containing full length
open reading frame (ORF) of the GnTII using primers CeGnTII-
for (59- GAC TTG ATC ACC CGG GAT GAT GGT CTA
TCG ACG GAT G -39) and CeGnTII-rev (59- TGC ATC AGC
TGC TAG CTT AAG AAG TTG TAG ATG TGA TTG T -39).
The product was digested with NheI/XmaI and ligated into
pUCDM vector (EMBL, Grenoble) cut with same enzymes,
resulting in pUCDM-G. The bovine ß1,4-galactosyltransferase I
(GalT) was PCR amplified from a plasmid containing full length
ORF of the GalT using primers b4GalT-for (59- CAT CGG GCG
CGG ATC CAT GAA GTT TCG GGA GCC GCT -39) and
b4GalT-rev (59- GAC TGC AGG CTC TAG ACT AGC TCG
GCG TCC CGA TG -39). The product was digested with
BamHI/XbaI and ligated into pUCDM-G vector cut with the
same enzymes resulting in pUCDM-GG. The resulting glyco-
module was introduced in the loxP site of a MultiBac genome,
using DH10MultiBac
Cre cells according to Fitzgerald et al. [18].
The hence generated DH10MultiBac
Glyco cells were then used as a
basis for the generation of a recombinant baculovirus expressing
an IgG1 antibody.
Construction of SweetBac expressing human IgG1 heavy
and light chain genes
The human HIV anti-gp41 IgG1 antibody 3D6 [22] was used as
a model protein. The antibody light chain was PCR amplified
using primers LC-SpeI-for (59- AGTAGTAGTACTAGTATG-
GACATGAGGGTCCCCG -39) and LC-HindIII-rev (59- AG-
TAGTAGTAAGCTTCTAACACTCTCCCCTGTTGAAGC -
39). The product was digested with SpeI/HindIII and ligated into
pFastBac Dual (Invitrogen, Carlsbad, USA) vector cut with same
enzymes, resulting in pFBD-LC. The dsDNA encoding 3D6 heavy
chain was PCR amplified using primers HC-XhoI-for (59-
AGTAGTAGTCTCGAGATGGAGTTGGGACTGAGCTG -
39) and HC-NheI-rev (59- AGTAGTAGTGCTAGCTCATT-
TACCCGGAGACAGGG -39). The product was XhoI/NheI
digested and ligated into XhoI/NheI digested pFBD-LC, resulting
in pFBD-3D6. The pFBD-3D6 plasmid was inserted into the Tn7
site of the previously generated SweetBac (see ‘‘Construction of
SweetBac’’ section above) using DH10MultiBac
Glyco cells allowing
generation of SweetBac-3D6 according to standard procedures. As
a negative control, the pFBD-3D6 plasmid was inserted in a ‘‘wild-
type’’ bacmid using DH10MultiBac cells followed by generation of
virus according to standard procedures.
Expression and purification of mAb 3D6
Tnao38 and Hi5 cells were transferred to shaker flasks with
supplemented IP-L41 medium without FCS two days prior to
infection. For infection, 5610
7 cells were spun down at 9006g for
10 min, resuspended in 50 mL fresh IP-L41 medium and infected
with a multiplicity of infection (MOI) of 5. All expressions were
carried out in triplicate. To generate an expression profile, samples
were taken from 24 to 168 hours post infection (hpi) every
24 hours. For standardisation of further experiments, supernatants
of Tnao38 and Hi5 cells were harvested 96 hpi by centrifugation at
2000 g for 10 min.
The cellular supernatant was filtered through a 0.22 mM filter
cartridge (Millipore, Billerica, USA) and applied on a 1 mL Bio-
Scale
TM Mini UNOsphere SUPrA
TM Cartridge (BioRad, Hercu-
les, USA) using an A ¨kta purifier (GEHealthcare). Elution was
performed with 100 mM glycine/HCl buffer pH 3. To increase
stability, the eluted samples were adjusted to pH 7 using 100 mM
Tris-HCl (pH 9).
Enzyme-linked Immunosorbent Assay
Coating of 96 well Maxisorp plates (Nunc, Roskilde, Denmark)
was performed by incubating 100 mL anti-Human IgG (c-chain
specific) antibody (Sigma Aldrich, I3382) (diluted 1:1000 in
coating buffer: PBS, 1% BSA) at 4uC over night. Plates were
washed with TPBS (PBS, 0.1% Tween20) and 50 mL serially
Insect Cells for the Production of Glycoproteins
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to the wells. After one hour incubation on a rocking platform, the
plates were washed again with TPBS. Detection was performed
with 50 mL/well of an anti-human k light chain peroxidase
conjugate (Sigma Aldrich, A7164) 1:1000 diluted in dilution buffer
for 1 h while rocking. Staining of the ELISA plates was performed
by adding 100 mL/well staining buffer (sodium citrate buffer, pH5)
containing 1 mg/mL OPD (1,2-o-phenylenedihydrochloride) and
1 mL/mL H2O2 (35%). The reaction was stopped with 100 mL
H2SO4 and plates were analysed on an InfiniteH M1000 reader
(Tecan Group, Ma ¨nnedorf, Switzerland).
SDS-PAGE and lectin blotting
Samples were mixed with 26electrophoresis buffer containing
250 mM Tris/HCl, pH 6.8, 10% glycerol, 2% SDS, 100 mM
DTT and 0.1% bromophenol blue. Proteins were separated by
SDS-Page according to Laemmli [23]#, stained with colloidal
Coomassie or electroblotted onto a nitrocellulose membrane (Pall,
Port Washington, USA). Detection was performed using biotiny-
lated Ricinus communis agglutinin I (RCA I) (Vector Labs, B-1085)
in TPBS (PBS+0.05% Tween 20) and streptavidin-conjugated
alkaline phosphatase (Vector-Labs, SA-5100). The blot was
developed using NBT/BCIP Sigma fast tablets (Sigma, B5655).
N-glycan analysis
N-glycan analyses were essentially performed as described in
Rendic et al. [24]. Briefly, after the heavy and light chains of
purified IgG1 were separated on an SDS-PAGE, bands corre-
sponding to heavy chains were excised. After washing the bands,
they were treated with dithiothreitol and iodoacetamide solutions
to modify cysteine residues. The gel bands were washed again and
then subjected to trypsin digestion at 37uC over night. The
peptides extracted with AcN:H2O:TFA solution (acetonitrile/
water/trifluoroacetic acid; 666:333:1) were then dried, resus-
pended in 20 ml of 50 mM ammonium acetate (pH 5) buffer and
subjected to PNGase A treatment at 37uC over night. The released
N-glycans were separated from peptides by using columns packed
with 10 mL LiChroprep RP 18 (25–40 mM) reversed phase resin
(Merck) on top of 40 mL Dowex 50WX8-400 ion exchange resin
(Sigma, 217514). After equilibrating the column with 2% acetic
acid, the sample was applied, the column was washed with 2%
acetic acid and the flow-through containing N-glycans was
collected. For further purification of the released N-glycans,
columns were packed with Supelclean
TM ENVI-Carb
TM PGC
material (Sigma) on top of LiChroprep RP 18 (25–40 mM)
reversed phase resin (Merck) and equilibrated with 2% acetic
acid. The samples were loaded on the column and after washing
with H2O, the N-glycans were eluted with 40% acetonitrile. The
purified N-glycans were dried in a SpeedVac, finally resuspended
in 5 mL deionised water and used for MALDI-TOF-MS analysis
(on a Bruker Ultraflex MALDI-TOF/TOF in positive reflectron
mode) using 6-aza-2-thiothymine (ATT) as matrix.
Flow cytometric analysis
Sf9 cells were infected with a recombinant baculovirus
expressing the HIV gp41 3D6 epitope (SGKLICTTAVPWNAS)
on the cellular surface with MOI 10 and harvested 72 hpi. After
brief washing with phosphate buffered saline (PBS), 1610
6 cells
were incubated with 100 mL of mammalianised/‘‘wild-type’’ 3D6
antibody (1 mg/mL in PBS containing 10% FCS) for 1 h at room
temperature while gently shaking. Cells were again washed with
PBS and incubated with an anti-human IgG (c-chain specific) R-
phycoerythrin conjugate (Sigma-Aldrich, P8047) in PBS contain-
ing 10% FCS for 1 h at room temperature. After a final wash with
PBS, cells were resuspended in 400 mL PBS and analysed on a
FACS-CantoII (Becton Dickinson, San Jose, CA).
Human U937 leukemic monocyte lymphoma cells were washed
with PBS and incubated with 100 mL of mammalianised/‘‘wild-
type’’ 3D6 antibody (1 mg/mL in PBS) for 1 h at room
temperature while gently shaking. After a brief washing, cells
were incubated with an anti-human k light chain FITC conjugate
(Sigma Aldrich, F3761). Cells were finally washed with PBS,
resuspended in 400 mL PBS and analysed on a FACS-CantoII.
Results
Construction of SweetBac
Our aim was to develop a virus backbone, facilitating flexible
modifications of the N-linked glycosylation capacity of Sf9, Sf21,
Hi5 and Tnao38 insect cells. Previous results have shown that
mammalian b1,4-galactosyltransferase I (GalT) can efficiently
modify the glycosylation of insect cells [9]#. Our own data further
indicate that the invertebrate GLY-20 N-acetylglucosaminyltrans-
ferase II (GnTII) of C. elegans, whose temperature optimum is near
to that where insect cells are grown, was well expressed in Sf9 cells
(Wang H., Rendic D., unpublished data). Therefore, we
constructed a glyco-module coding for a C. elegans GnTII and a
bovine GalT controlled by p10 and polyhedrin (ph) promoter
respectively. This module was integrated into the loxP site of a
MultiBac genome. The resulting SweetBac was then used as a
basis for the production of recombinant glycoproteins with
mammalianised complex type N-glycans. In order to evaluate
the functionality of SweetBac, we additionally introduced heavy
(HC) and light chain (LC) open reading frames of the human HIV
anti-gp41 antibody 3D6 [22] in the Tn7 site of a SweetBac
genome, resulting in SweetBac-3D6. As a negative control, open
reading frames coding the heavy and the light chains of the same
antibody were integrated in a ‘‘wild-type’’ MultiBac genome as
well (Figure 1).
Figure 1. Schematic representation of SweetBac. Ag l y c o -
module, consisting of the open reading frames of the C. elegans N-
acetylglucosaminyltransferase II (GnTII) and the bovine b4-galactosyl-
transferase I (GalT), was integrated in the loxP site of a MultiBac genome
resulting in SweetBac. The generated viral backbone was subsequently
used for the expression of 3D6 antibody heavy (HC) and light (LC) chain
genes, by integrating them in the standard Tn7 site.
doi:10.1371/journal.pone.0034226.g001
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Hi5 and Tnao38 cells are both derived from Trichoplusia ni.
Previous studies have demonstrated higher yields, especially for
secreted proteins, when using Hi5 cells [15]. In order to evaluate
antibody expression yields for both cell lines, we infected Tnao38
and Hi5 cells with a recombinant baculovirus expressing 3D6
antibody at an MOI of 5 and took samples every 24 hours up to 4
or 7 days; Hi5 cells started to lyse after 4 days and thus, were not
Figure 2. Expression of 3D6 antibody in lepidopteran insect cells. (A) Tnao38 and Hi5 cells were infected in triplicate with recombinant
baculovirus expressing 3D6 antibody. Samples were taken every 24 h and the amount of secreted antibody was measured by ELISA. (B) Tnao38 and
Hi5 cells were again infected in triplicate with recombinant baculovirus (Tnao38, Hi5) and SweetBac virus (Tnao38 glyco, Hi5 glyco) expressing 3D6
antibody. Samples were taken 72 and 96 hours post infection (hpi) and the amount of secreted antibody was measured by ELISA. Significance of the
results was confirmed by Student’s t-test (p-value,0,05).
doi:10.1371/journal.pone.0034226.g002
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measured by ELISA. Figure 2A shows that the secretion profile
among the two cell lines was similar within the first 96 hours post
infection (hpi). Tnao38 and Hi5 cells yielded around 1 mgo f
secreted antibody/ml cell culture supernatant 24 hpi, steadily
increasing to 9.5 and 12 mg respectively at 96 hpi. Tnao38 cells
were more stable, allowing the expression to be expanded up to
168 hpi. A continuous increase in antibody secretion could be
detected, yielding up to 30 mg/ml on day 7. These data indicate
that Tnao38 cells are even more robust than Hi5 cells and suggest
them to be, at least for this antibody, highly suitable for large scale
protein production.
To evaluate whether co-expression of the glycosyltransferases
has an impact on target gene expressions, we infected Tnao38 and
Hi5 cells with a SweetBac virus expressing the 3D6 antibody
(SweetBac-3D6) and with standard baculovirus expressing 3D6.
Samples were analysed at 72 hpi and 96 hpi for both cell lines.
Figure 2B shows that at 72 hpi, the amounts of secreted 3D6
antibody from Tnao38 and Hi5 cells decreased 18% as compared
to 3D6 expression without glycosyltransferase genes in the
baculovirus genome. At 96 hpi, the yields were 25% lower for
Tnao38 cells and 30% lower for Hi5 cells when SweetBac-3D6 was
used. Significance of the results was confirmed by Student’s t-test
(p-value,0.05).
Testing the glycosylation of 3D6
For testing the functionality of SweetBac, purified 3D6
antibodies were subjected to SDS-PAGE and electroblotted to a
nitrocellulose membrane. The presence of galactose residues was
detected by incubating the blot with Ricinus communis agglutinin I
(RCA I), specific for terminal galactose [25]#. Figure 3 shows that
although similar protein amounts of antibody heavy chains were
loaded on the gel, RCA I bound to only mammalianised variants
(HiGlyco and Tn38Glyco). These results confirmed the desired
change in glycosylation, indicating proper functionality of the
integrated glycosyltransferases. 3D6 derived from Chinese hamster
ovary cells (CHO) as well as one derived from Mimic Sf9 cells, a
cell line containing a human N-acetylglucosaminyltransferase I,
human N-acetylglucosaminyltransferase II, rat b1,4-galactosyl-
transferase I, mouse a2,3-sialyltransferase and mouse a2,6-
sialyltransferase [12] served as controls.
N-glycan analysis
In order to confirm the results obtained with lectin blotting, we
analyzed the N-glycosylation patterns of the different 3D6
antibodies by mass spectrometry. Figure 4 shows the MALDI-
TOF-MS spectra of PNGase A released IgG1 N-glycans from
mammalianised and ‘‘wild-type’’ Tnao38 and Hi5 cells. The 3D6
expressed in Tnao38 cells carries mainly single and double
fucosylated tri-mannose structures, partly with one terminal N-
acetylglucosamine. 3D6 antibodies from mammalianised Tnao38
cells on the other hand showed mainly complex, singly fucosylated
biantennary N-glycan structures carrying two terminal N-acet-
ylglucosamine residues (,30%), one terminal galactose (,30%) or
two terminal galactose residues (,20%). N-glycans from Hi5 cell
expressed 3D6 closely resemble those found from Tnao38 cells, but
are more highly galactosylated. The portion of complex
biantennary structures was as high as ,80% from mammalianised
variants with ,50% carrying two terminal galactose residues.
Functionality of 3D6
In order to evaluate the target binding ability of the different
3D6 antibodies, we infected Sf9 cells with a recombinant
baculovirus expressing the HIV gp41 epitope (SGKLICT-
TAVPWNAS) on the cellular surface. The epitope-presenting
cells were incubated with 3D6 antibody and analysed by FACS.
Figure 5A shows that the binding characteristics were equal for all
antibody preparations, indicating the same specificity and affinity.
Besides target binding, the ability of an antibody to elicit
glycosylation dependent effector functions was evaluated. Human
U937 leukemic monocyte lymphoma cells that are known to
express the human Fc gamma receptor I (CD64) on their cellular
surface were incubated with 3D6 antibody samples and receptor
binding was again analysed by FACS. Figure 5B shows that
binding characteristics of antibodies produced in Hi5 and Tnao38
cells were comparable. However, the peaks resulting from samples
derived from SweetBac-3D6 infected cell lines are shifted in both
cases. This increase in binding capacity indicates the importance
of proper, mammalian-like N-glycosylation for recombinantly
expressed antibodies [26–28].
Discussion
The presence of specific N-linked glycan structures is of great
importance for the full functionality of therapeutically active
proteins. Mammalian cells, especially Chinese hamster ovary
(CHO), human embryonic kidney (HEK) and mouse myeloma
(NS0) cells, are currently the favoured cell lines for the production
of functional proteins like antibodies, because of high yields and
their ability to generate complex type N-glycans [29,30]. A major
drawback in the field of mammalian cell technology is the either
time consuming top-clone selection for generating transgenic cell
lines, the labour-intensive transfection procedures for transient
expressions or, occasionally, the occurrence of allergenic a1,3-
galactose [31]. The baculovirus-insect cell system may have an
advantage over stably transfected CHO cells, when considering a
need for fast and easy production systems which may get
increasingly important in the future due to novel, ‘‘personalised’’
medical treatments or when time consuming production schemes
are not acceptable.
Based on data proposing that Hi5 cells are more suitable for
expressing high amounts of secreted proteins as compared to the
commonly used Sf9 cells [15,16], we chose to evaluate the
expression capacity of Hi5 cells and the newly established Tnao38
cell line [5]#. Using Tnao38 cells, the expression could be
expanded up to 7 days post infection because of very high cellular
stability. In the end, the amount of secreted 3D6 antibody was as
high as 30 mg/mL cell culture supernatant, which is approaching
production levels of transient expressions in mammalian cells
(Figure 2). The higher robustness of this cell line might be an
Figure 3. Lectin Blot using Ricinus communis agglutinin I. Cellular
supernatants were harvested 96 hpi and purified 3D6 antibodies were
separated on SDS-PAGE and binding of biotinylated Riccinus communis
agglutinin I to antibody heavy chains was tested. The lectin only bound
SweetBac expressed antibodies (Hi5Glyco, Tn38Glyco), because of
terminal galactose present on N-glycans. CHO and Mimic insect cell
expressed antibodies were used as controls.
doi:10.1371/journal.pone.0034226.g003
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virulent infectious cycle is also reflected by 1–2 magnitudes lower
baculovirus titres in the supernatant as compared to Sf9 cells (data
not shown). The lower baculovirus titres in the supernatant are
expected to reduce issues in downstream processing facilitating
quicker and more effective steps towards acquiring pure (and
virus-free) recombinantly produced protein.
In this study we further evaluated the possibility to mamma-
lianise the insect glycosylation machinery by a viral-based
approach in order to provide a flexible protein production
platform suitable for various insect cell lines. The differences in
N-glycan processing between insect and mammalian cells are due
mainly to insignificant expression of glycosyltransferases respon-
sible for generating complex-type structures. Glycoengineering in
insect cells is based mainly on the pioneering work of Jarvis and
co-workers and is generally performed by stably integrating
enzymes into the cellular genome of Sf9 cells [12,13]. This,
however, is a very time consuming process and a flexible choice of
the most suitable cell line is lost. In a previous study we have
furthermore shown that Sf9 cells are not always the ideal choice
when it comes to the production of secreted proteins in high yields
[16]#.
Our approach to provide a more flexible glycosylation to a wide
range of insect cell lines is based on the MultiBac technology [17–
20] which is feasible for the expression of multiple genes from one
baculovirus backbone. We integrated the C. elegans N-acetylgluco-
Figure 4. MALDI-TOF-MS spectra of 3D6 IgG1 N-glycans. N-glycan structures of an IgG1 antibody expressed in Tnao38 (A) and Hi5 (C) cells
(96 hpi) mostly consist of single and double fucosylated tri-mannose structures with maximally one terminal N-acetylglucosamine. The spectra of the
mammalianised cells (B, D) show a shift of the dominant structures towards higher m/z values. Fucosylated biantennary N-glycan structures carrying
two N-acetylglucosamine residues with one or two terminal galactose residues were identified as dominant N-glycan on IgG1 recombinantly
expressed in Tnao38 cells using SweetBac (B). The N-glycan structures identified from IgG1 expressed in Hi5 cells using SweetBac (D) resemble the
ones found in SweetBac infected Tnao38 cells with an even higher dominance of terminal galactose. Oligomannosidic glycans (Man5–6GlcNAc2) are
indicated by asterisks. Graphical representations of glycans are consistent with the nomenclature of the Consortium for Functional Glycomics.
doi:10.1371/journal.pone.0034226.g004
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transferase I (GalT) into the backbone of a standard MultiBac
virus, resulting in a recombinant baculovirus designated as
SweetBac. We further inserted heavy and light chain genes of
the human HIV anti-gp41 IgG1 antibody 3D6 [22] as a model,
resulting in the baculovirus vector SweetBac-3D6. A great
advantage of this setup is that the enzymes necessary for
glycosylation as well as the genes of interest are present on one
single baculoviral vector. Co-expression of proteins in one cell by
co-infection of two or more recombinant baculovirus clones is
generally possible. However, the use of multiple baculovirus clones
for co-infection decreases the chances that all required genes are
delivered to all cells in the population.
Studies have already reported the expression of glyco-modifying
enzymes and target protein from the same viral vector, however,
integration was based on a quadruple transfer-vector with a size of
16.6 kb [32]#. This approach limits the possibility of integrating
further enzymes and/or target proteins. The reason for initially
focussing on two glycosyltransferases was the fact that proper
sialylation requires a whole set of enzymes and thus, is beyond the
scope of demonstrating the proof of concept [13]. However, the
existing SweetBac virus may further be modified by integrating
respective expression cassettes into its backbone.
When SweetBac-3D6 was used to infect Hi5 and Tnao38 cells
the yield of antibody was significantly reduced as compared to
expression without a glycosylation module. This might be due to
the very strong promoters used for the expression of glycosyl-
transferases. Using the weak immediate early promoter IE1,
providing proper glycosylation earlier during the infection cycle,
might have a positive impact on the product as well.
In order to evaluate the actual change in glycosylation of 3D6,
we performed a lectin blot detecting terminal galactose. Figure 3
shows that specific binding was only detected with mammalianised
antibodies indicating a proper functionality of the introduced
glycosyltransferases. As a conformation, we analysed PNGase A
released N-glycans by MALDI-TOF-MS. Indeed, SweetBac-3D6
Figure 5. Binding of insect cell expressed 3D6 antibodies to 3D6 epitope and human FccRI. Sf9 cells presenting the 3D6 epitope were
incubated with purified antibodies and target binding was analysed by FACS. Antibodies expressed in Hi5 and Tnao38 cells using standard
baculoviral vectors (Hi5, Tnao38) as well as SweetBac (Hi5 Glyco, Tnao38 Glyco) show a highly specific binding. The broadening of the peaks can be
explained by different amounts of 3D6 epitope displayed on Sf9 cells (A). Binding of antibodies to human Fc gamma receptor I was measured by
incubating 3D6 antibodies with U937 cells. FACS analysis showed that all antibodies bound FccRI present on the cellular surface, but the binding of
SweetBac expressed variants (Hi5 Glyco, Tnao38 Glyco) was significantly increased.
doi:10.1371/journal.pone.0034226.g005
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with one or two terminal galactose residues. Nevertheless, the
amount of galactosylated glycans on IgGs expressed in mamma-
lianised Hi5 cells is significantly higher (,50% compared to
,20% in Tnao38 cells) (Figure 4). In terms of the degree of
galactosylation, SweetBac mammalianised Tnao38 cells produced
IgG akin to that observed for CHO cells [16]. However, Tnao38
cell derived IgGs also carried more paucimannosidic structures,
lacking terminal GlcNAc or galactose; these types of glycans are
only present at low levels on IgGs expressed by Hi5 cells and are
absent from CHO cells.
It is known that the N-linked glycosylation of an IgG1 antibody
strongly influences the ability to exert effector functions like
antibody-dependent cellular cytotoxicity (ADCC). We therefore
investigated the binding of 3D6 to human Fcc receptors present
on human U937 leukemic monocyte lymphoma cells, as well as
the binding to its target. The presence of a more complex N-
glycan structure did not influence target binding (Figure 5A), but
binding to Fc receptors was significantly enhanced (Figure 5B),
indicating that one can improve the efficacy of insect cell expressed
antibodies by co-expressing two key glycosyltransferases using the
SweetBac system. As insect cell expression system has been gaining
more importance during the past years [1], and new cell lines are
being established [5], we aim to provide a flexible tool for
production of custom-designed individual products at sufficient
yields and within a reasonable time frame.
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